TY - JOUR T1 - Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health JF - Pharmacological Reviews JO - Pharmacol Rev SP - 1 LP - 19 DO - 10.1124/pr.118.016253 VL - 71 IS - 1 AU - Cheng, Feixiong AU - Liang, Han AU - Butte, Atul J. AU - Eng, Charis AU - Nussinov, Ruth A2 - Gottesman, Michael M. Y1 - 2019/01/01 UR - http://stonel.info/content/71/1/1.abstract N2 - Recent remarkable advances in genome sequencing have enabled detailed maps of identified and interpreted genomic variation, dubbed “mutanomes.” The availability of thousands of exome/genome sequencing data has prompted the emergence of new challenges in the identification of novel druggable targets and therapeutic strategies. Typically, mutanomes are viewed as one- or two-dimensional. The three-dimensional protein structural view of personal mutanomes sheds light on the functional consequences of clinically actionable mutations revealed in tumor diagnosis and followed up in personalized treatments, in a mutanome-informed manner. In this review, we describe the protein structural landscape of personal mutanomes and provide expert opinions on rational strategies for more streamlined oncological drug discovery and molecularly targeted therapies for each individual and each tumor. We provide the structural mechanism of orthosteric versus allosteric drugs at the atom-level via targeting specific somatic alterations for combating drug resistance and the “undruggable” challenges in solid and hematologic neoplasias. We discuss computational biophysics strategies for innovative mutanome-informed cancer immunotherapies and combination immunotherapies. Finally, we highlight a personal mutanome infrastructure for the emerging development of personalized cancer medicine using a breast cancer case study. ER -